Dilemma of immunosuppression and infection risk in systemic lupus erythematosus.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36987605.
- Also identified by DOI 10.1093/rheumatology/keac678 and PMC identifier 10050939.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with SLE are at high risk of various infections as evidenced by a number of studies. The main determinants of infection in SLE are disease activity, organ damage, and often inevitable medication. The molecular and cellular mechanisms underlying infection remain unclear. Impaired immunity, immunosuppressants and corticosteroids clearly increase the risk of infection, whereas some medications, such as low-dose IL-2, hydroxychloroquine and IVIG are safe in SLE patients with substantial evidence. It is important to balance the immunosuppression and infection risks in practice. This article focuses on medication-related infections in SLE and discusses the therapeutic options for the disease in clinical practice.
Medical subject headings
- Lupus Erythematosus, Systemic
- Infections